Published: 2018-12-26

Cost comparison of antihypertensive drugs available in India with Drugs Prices Control Order price list

Rahul Kumar, Narendra Kumar, Akhlaque Ahmad, Manoj Kumar, Rajendra Nath, Rakesh Kumar Dixit, Sarvesh Singh


Background: DPCO (Drugs Prices Control Order) price list is issued by NPPA (National Pharmaceutical Pricing Authority) each year to guide the pharmaceuticals companies for controlling the prices in India. Some drugs cost more than the DPCO list. As antihypertensive drugs are taken lifelong once diagnosis is made, price variation and costing above prescribed price cause a huge economic burden on such patients. This study was undertaken to know the number of antihypertensive drugs brands with price above the recommended DPCO price list 2017.

Methods: Authors have collected the data from website, CIMS (current index of medical specialties), Drug Today, and compared the listed antihypertensive drugs of various available brands in India with DPCO price list 2017. Data was entered in Microsoft excel 2010. Percentage of selling price above the DPCO price list was calculated for each drug.

Results: The data of 30 formulations of 16 antihypertensive drugs was analysed. The total number of available brands of all formulations was 1365 out of which only 831 (60.88%) brands were found to have price <DPCO recommended list. 534 (39.12%) brands had price more than the recommended limit. The minimum violation of price limit was found in case of metoprolol 25mg (6.66%) and maximum price violation was observed with spironolactone 25mg and sodium nitroprusside inj 10mg/ml.

Conclusions: Reassessment and monitoring for implementation of DPCO price list should be done as still large number of brands are not following the regulations and are violating the limit set by NPPA/DPCO.


Antihypertensives, Drug price, DPCO, NPPA

Full Text:



Anchala R, Kannuri NK, Pant H, Khan H, Franco OH, Angelantonio ED, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32(6):1170-7.

Banerji A. Review of Asia-Pacific's healthcare systems with emphasis on the role of generic pharmaceuticals. Academy of Health Care Management J. 2013;9(1/2):53A.

Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, et al. Prices and availability of common medicines at six sites in India using a standard methodology. Indian J Med Res. 2007;125:645-54.

DPCO, Drug Price Control Order 2013 - National Pharmaceutical Pricing Authority; 2013. Available at:

MedGuide India; 2018. Available at:

Antihypertensive drugs. In: Current Index of Medical specialities. UBM Medica India Private Limited, Bangalore; Jan-Apr 2018:104-130.

Antihypertensive drugs. In: Drug today. Lorina Publications (I) Inc, Delhi; Apr-Jun 2018:227-244.

Kumar R, Manu C, Singh DK, Lakhani P, Tutu S, Dixit R. The extent of price variation amongst branded antihypertensive drugs and its association with number of pharmaceutical companies. Int J Res Med Sci. 2015;3(10):2800-6.

Ahmad A, Patel I, Sanyal S, Balkrishnan R, Mohanta GP. Availability, cost and affordability of antimalarial medicines in India. Int J Pharm Clin Res. 2014;6:7-12.

Harvard School of Public Health, Boston, MA, USA. How Effective Is India's Drug Price Control Regime? 2007. Available at:

Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines? Study of the impact of drug price control order on sales volume of drugs in India. 2014;34(4):64-65.

DPCO Impact: Pharma cos growth suffers for drugs under price ceiling/ Business Standard News, 2013. Available at:

Vernon, John A, Golec JH, and Hughen WK. The Economics of Pharmaceutical Price Regulation and Importation: Refocusing the Debate. Amer J Law Medi. 2006;32:175-92.

Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet. 2011;377(9764):505-15.